Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma
SEATTLE, Oct. 16, 2023 -- Perspective Therapeutics, Inc. , today announced the completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01 , its...
United States Markus Puhlmann Zacharys Morris Exchange Commission Department Of Energy University Of Wisconsin Bentson Research Fellowship
Source: marketscreener.com